These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23607633)

  • 61. The influence of body mass index on the tolerability and effectiveness of full-weight-based paclitaxel chemotherapy in women with early-stage breast cancer.
    Lin L; Soesan M; van Balen DEM; Beijnen JH; Huitema ADR
    Breast Cancer Res Treat; 2022 Oct; 195(3):325-331. PubMed ID: 35974240
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [A case of multiple intestinal perforation secondary to paclitaxel and carboplatin combined chemotherapy for lung cancer].
    Liu ZC; Wu D; Lan SJ; Wang DD
    Zhonghua Zhong Liu Za Zhi; 2019 May; 41(5):399-400. PubMed ID: 31137178
    [No Abstract]   [Full Text] [Related]  

  • 63. Repeated arthralgia associated with granulocyte colony stimulating factor administration.
    Tsukadaira A; Okubo Y; Takashi S; Kobayashi H; Kubo K
    Ann Rheum Dis; 2002 Sep; 61(9):849-50. PubMed ID: 12176817
    [No Abstract]   [Full Text] [Related]  

  • 64. Eruptive purpuric papules on the arms; a case of chemotherapy-induced inflammation of actinic keratoses and review of the literature.
    Chambers CJ; Liu H; White CR; White KP; Sharon VR
    Dermatol Online J; 2014 Jan; 20(1):21246. PubMed ID: 24456949
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Retrospective analysis of the carboplatin dosage and relationship with toxicity in cancer patients].
    García Palomo M; Castellanos Clemente Y; Díez Fernández R; Martínez Sesmero JM; Iglesias Bolaños AM; Hernández Muniesa B
    Farm Hosp; 2007; 31(4):218-22. PubMed ID: 18052616
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Monitoring for potential adverse drug reactions in patients receiving chemotherapy.
    Ikesue H; Ishida M; Uchida M; Harada M; Haro T; Mishima K; Itoh Y; Kotsubo K; Yoshikawa M; Oishi R
    Am J Health Syst Pharm; 2004 Nov; 61(22):2366, 2368-9. PubMed ID: 15581259
    [No Abstract]   [Full Text] [Related]  

  • 67. Actual body weight for determining doses of chemotherapy in obese cancer patients: evaluation of treatment tolerability.
    Abdah-Bortnyak R; Tsalic M; Haim N
    Med Oncol; 2003; 20(4):363-8. PubMed ID: 14716032
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Chemotherapy dosing in overweight and obese patients with cancer.
    Lyman GH; Sparreboom A
    Nat Rev Clin Oncol; 2013 Aug; 10(8):451-9. PubMed ID: 23856744
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Appropriate chemotherapy dosing in obese patients with cancer.
    Lyman GH; Sparreboom A
    Nat Rev Clin Oncol; 2013 Nov; 10(11):664. PubMed ID: 24101119
    [No Abstract]   [Full Text] [Related]  

  • 70. Obesity Paradox in Lung Cancer Prognosis: Evolving Biological Insights and Clinical Implications.
    Zhang X; Liu Y; Shao H; Zheng X
    J Thorac Oncol; 2017 Oct; 12(10):1478-1488. PubMed ID: 28757418
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sarcopenia and chemotherapy dosing in obese patients.
    Laviano A; Rianda S; Rossi Fanelli F
    Nat Rev Clin Oncol; 2013 Nov; 10(11):664. PubMed ID: 24101124
    [No Abstract]   [Full Text] [Related]  

  • 72. Exploring the Impact of the Obesity Paradox on Lung Cancer and Other Malignancies.
    Nitsche LJ; Mukherjee S; Cheruvu K; Krabak C; Rachala R; Ratnakaram K; Sharma P; Singh M; Yendamuri S
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326592
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors.
    Khaddour K; Gomez-Perez SL; Jain N; Patel JD; Boumber Y
    Front Oncol; 2020; 10():576314. PubMed ID: 33194687
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium.
    Shepshelovich D; Xu W; Lu L; Fares A; Yang P; Christiani D; Zhang J; Shiraishi K; Ryan BM; Chen C; Schwartz AG; Tardon A; Wu X; Schabath MB; Teare MD; Le Marchand L; Zhang ZF; Field JK; Brenner H; Diao N; Xie J; Kohno T; Harris CC; Wenzlaff AS; Fernandez-Tardon G; Ye Y; Taylor F; Wilkens LR; Davies M; Liu Y; Barnett MJ; Goodman GE; Morgenstern H; Holleczek B; Brown MC; Liu G; Hung RJ
    J Thorac Oncol; 2019 Sep; 14(9):1594-1607. PubMed ID: 31163278
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Genetic screening reveals a link between Wnt signaling and antitubulin drugs.
    Khan AH; Bloom JS; Faridmoayer E; Smith DJ
    Pharmacogenomics J; 2016 Apr; 16(2):164-72. PubMed ID: 26149735
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Toxicity and prognosis in overweight and obese women with lung cancer receiving carboplatin-paclitaxel doublet chemotherapy.
    Kashiwabara K; Yamane H; Tanaka H
    Cancer Invest; 2013 May; 31(4):251-7. PubMed ID: 23607633
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
    Kelly K; Pan Z; Murphy J; Huffman DH; Bunn PA
    Clin Cancer Res; 1997 Jul; 3(7):1117-23. PubMed ID: 9815791
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
    Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.
    Hensing TA; Peterman AH; Schell MJ; Lee JH; Socinski MA
    Cancer; 2003 Aug; 98(4):779-88. PubMed ID: 12910523
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
    Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M
    Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.